KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBIT: 2019-2024

Historic EBIT for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Dec 2024 value amounting to -$559.8 million.

  • Ginkgo Bioworks Holdings' EBIT fell 63.06% to -$90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.1 million, marking a year-over-year increase of 45.11%. This contributed to the annual value of -$559.8 million for FY2024, which is 35.24% up from last year.
  • Ginkgo Bioworks Holdings' EBIT amounted to -$559.8 million in FY2024, which was up 35.24% from -$864.4 million recorded in FY2023.
  • Ginkgo Bioworks Holdings' 5-year EBIT high stood at -$137.0 million for FY2020, and its period low was -$2.2 billion during FY2022.
  • Moreover, its 3-year median value for EBIT was -$864.4 million (2023), whereas its average is -$1.2 billion.
  • In the last 5 years, Ginkgo Bioworks Holdings' EBIT slumped by 1,234.38% in 2021 and then spiked by 60.87% in 2023.
  • Yearly analysis of 5 years shows Ginkgo Bioworks Holdings' EBIT stood at -$137.0 million in 2020, then crashed by 1,234.38% to -$1.8 billion in 2021, then decreased by 20.81% to -$2.2 billion in 2022, then skyrocketed by 60.87% to -$864.4 million in 2023, then spiked by 35.24% to -$559.8 million in 2024.